Arch Biopartners Inc. (8HA)

Profile

https://www.archbiopartners.com

Arch Biopartners Inc. is a Canadian therapeutic biotechnology company focused on developing novel drug candidates to prevent and treat kidney-related injury and disease. Headquartered in Toronto, it concentrates on both acute kidney injury and chronic kidney disease, conditions that represent a significant burden in critical care and chronic medicine. The company’s pipeline includes LSALT peptide, designed to address inflammation-related acute kidney injury in high-risk settings such as major surgery, and cilastatin, aimed at reducing toxin-induced kidney damage. Arch Biopartners also advances AB569, targeting antibiotic-resistant bacterial infections and difficult-to-heal wounds, and the Borg platform, which uses proprietary peptides on metal and plastic surfaces to inhibit biofilm formation and reduce corrosion. Through these programs, Arch Biopartners occupies a specialized niche at the intersection of nephrology, critical care, and anti-infective therapies within the global biopharmaceutical market.